Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia

Dysregulation of MYBL2 has been associated to tumorigenesis and the S427G polymorphism could induce partial inactivation of MYBL2, associating it with cancer risk. It has previously been shown that MYBL2 was over-expressed in some acute myeloid leukemias (AML), portending poor prognosis. However, to date no studies have investigated the S427G or other genetic variants of MYBL2 in AML. This study analyzed the S427G in 197 AML patients and 179 controls and screened the MYBL2 sequence in patients. In contrast to other studies in solid tumors, the S427G was not associated with the incidence of AML. This study detected four unannotated genetic alterations, of which the Q67X could be involved in MYBL2 dysfunction. Eight polymorphisms were identified, among which the rs73116571, located in a splicing region, was associated with higher incidence in AML and weaker MYBL2 expression, suggesting pre-disposition to AML. Additional functional studies should be performed to verify these genetic variations as possible targets in AML.

[1]  P. Bolufer,et al.  Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients. , 2013, Leukemia research.

[2]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[3]  R. Kralovics,et al.  MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia , 2012, Leukemia.

[4]  J. Eyfjörd,et al.  Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome , 2011, Breast Cancer Research and Treatment.

[5]  M. Sana,et al.  miR-34a Induces the Downregulation of Both E2F1 and B-Myb Oncogenes in Leukemic Cells , 2011, Clinical Cancer Research.

[6]  Peichang Wang,et al.  B-MYB delays cell aging by repressing p16INK4α transcription , 2011, Cellular and Molecular Life Sciences.

[7]  J. Steitz,et al.  miR-29 and miR-30 regulate B-Myb expression during cellular senescence , 2010, Proceedings of the National Academy of Sciences.

[8]  A. Maya-Mendoza,et al.  B‐Myb is Critical for Proper DNA Duplication During an Unperturbed S Phase in Mouse Embryonic Stem Cells , 2010, Stem cells.

[9]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[10]  P. Wiernik.  F1000Prime recommendation of Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010 .

[11]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[12]  C. Perou,et al.  In Vitro and In Vivo Analysis of B-Myb in Basal-Like Breast Cancer , 2008, Oncogene.

[13]  Gabriela Kania,et al.  B-MYB Is Essential for Normal Cell Cycle Progression and Chromosomal Stability of Embryonic Stem Cells , 2008, PloS one.

[14]  G. Tonini,et al.  Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk , 2008, Oncogene.

[15]  J. Lipsick,et al.  Loss of Drosophila Myb interrupts the progression of chromosome condensation , 2007, Nature Cell Biology.

[16]  J. Frampton,et al.  The transcription factor B-Myb is essential for S-phase progression and genomic stability in diploid and polyploid megakaryocytes , 2006, Journal of Cell Science.

[17]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[18]  Arturo Sala,et al.  B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. , 2005, European journal of cancer.

[19]  Aravind Subramanian,et al.  A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[21]  S. Whittaker,et al.  Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. , 2003, Blood.

[22]  W. Sellers,et al.  Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. , 2002, Cancer research.

[23]  G. Ehninger,et al.  Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .

[24]  J. Lipsick,et al.  Mutation of the Drosophila homologue of the Myb protooncogene causes genomic instability , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Lothe,et al.  New insights into testicular germ cell tumorigenesis from gene expression profiling. , 2002, Cancer research.

[26]  G. Ramsay,et al.  Mutations in Drosophila myb lead to centrosome amplification and genomic instability. , 2002, Development.

[27]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[28]  H. van Dekken,et al.  Molecular cytogenetic evaluation of virus‐associated and non‐viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias , 2000 .

[29]  Y. Chen,et al.  Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. , 2000, Cancer research.

[30]  P. Meltzer,et al.  Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  B. Calabretta,et al.  B-myb alters the response of myeloid precursor cells to G-CSF. , 2000, Experimental cell research.

[32]  G. Tonini,et al.  Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. , 1999, Cancer research.

[33]  E. Reddy,et al.  The myb gene family in cell growth, differentiation and apoptosis , 1999, Oncogene.

[34]  B. Calabretta,et al.  Requirement of B- myb Function for Survival and Differentiative Potential of Human Neuroblastoma Cells (*) , 1995, The Journal of Biological Chemistry.

[35]  B. Calabretta,et al.  Growth regulated expression of B‐MYB in fibroblasts and hematopoietic cells , 1991, Journal of cellular physiology.

[36]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[37]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[38]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[39]  H. van Dekken,et al.  Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. , 2000, The Journal of pathology.

[40]  E. Lam,et al.  Cell-cycle regulation of human B-myb transcription. , 1995, Gene.

[41]  M. Arsura,et al.  Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells , 1991 .